Streetbeat News

Analyst Ratings

AON

Piper Sandler analyst Paul Newsome maintains a Neutral rating on Aon (NYSE:AON) and raises the price target from $306 to $326.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 3:23 pm

CBAY

VIAV

WISH

CymaBay Therapeutics shares surged 24.5% after Gilead Sciences announced its acquisition for $4.3 billion. Other stocks like ContextLogic, Iris Energy, and Viavi Solutions also recorded significant gains following various positive announcements, including asset sales, upgrades by analysts, and merger agreements.

Portfolio Pulse from Avi Kapoor

February 12, 2024 | 3:22 pm

AFRM

Affirm Holdings' stock price increased following BMO Capital's decision to maintain a Market Perform rating while raising its price target from $44 to $47.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 3:20 pm

TU

BMO Capital analyst Tim Casey has maintained an Outperform rating on TELUS, but lowered the price target from C$27 to C$26.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 3:19 pm

THG

Piper Sandler analyst Paul Newsome maintains an Overweight rating on Hanover Insurance Group (THG) and raises the price target from $143 to $147.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 3:16 pm

ELF

Significant bearish options activity has been detected for e.l.f. Beauty (NYSE:ELF), with a notable volume of trades aiming for a price range of $140.0 to $240.0 in the next three months. This unusual activity, comprising both puts and calls, suggests that major investors anticipate movement in ELF's stock price. Currently, ELF's stock is slightly up, with analysts providing mixed ratings and target prices ranging from $141 to $184. The company, known for its cosmetic products, generates most of its revenue from the US.

Portfolio Pulse from Benzinga Insights

February 12, 2024 | 3:16 pm

MGA

BMO Capital analyst Tamy Chen maintains an Outperform rating on Magna International (NYSE:MGA) but lowers the price target from $67 to $65.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 3:13 pm

AUTL

Autolus Therapeutics' stock price increased following Needham's decision to maintain a Buy rating and raise its price target from $8 to $9.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 3:12 pm

VIAV

Viavi Solutions' stock price increased following an upgrade from Stifel, moving from Hold to Buy, with a new price target set at $13, up from $10.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 3:10 pm

IIIV

BMO Capital analyst Rufus Hone maintains a Market Perform rating on i3 Verticals (NASDAQ:IIIV) and lowers the price target from $24 to $23.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 3:08 pm